Monitoring of minimal residual disease in acute myeloid leukemia

Critical Reviews in Oncology/Hematology

Volumn 56, Issue 2, 2005, Pages 283-309

  Kern, Wolfgang ^a   Schoch, Claudia ^a   Haferlach, Torsten ^a   Schnittger, Susanne ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Minimal residual disease; Multiparameter flow cytometry

Indexed keywords

CD45 ANTIGEN; DYE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; CELL COUNT; DIAGNOSTIC TEST; FLOW CYTOMETRY; FUSION GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYBRIDIZATION; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; NEPHROBLASTOMA; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVIEW; VALIDATION PROCESS;

FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 27644569879     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.06.004     Document Type: Review

References (204)

1. T. Buchner, W. Hiddemann, and B. Wormann Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group Blood 93 1999 4116 4124
2. W. Kern, T. Haferlach, and C. Schoch Risk-adapted therapy of AML: the AMLCG experience Ann Hematol 83 2004 59 61
3. B. Lowenberg, W. van Putten, and M. Theobald Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia N Engl J Med 349 2003 743 752
4. W. Kern, and E.H. Estey High-dose cytosine arabinos ide in induction treatment of acute myeloid leukemia: meta-analysis of three trials involving 1691 randomized patients Blood 100 2002 155a
5. M. Fopp, M.F. Fey, and M. Bacchi Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK) Ann Oncol 8 1997 251 257
6. R.J. Mayer, R.B. Davis, and C.A. Schiffer Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331 1994 896 903
7. R. Ohno, T. Kobayashi, and M. Tanimoto Randomized study of individualized induction therapy with or without vincristine, and of maintenance- intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group Cancer 71 1993 3888 3895
8. P.A. Cassileth, E. Lynch, and J.D. Hines Varying intensity of postremission therapy in acute myeloid leukemia Blood 79 1992 1924 1930
9. T. Buchner, D. Urbanitz, and W. Hiddemann Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group J Clin Oncol 3 1985 1583 1589
10. K.R. Rai, J.F. Holland, and O.J. Glidewell Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B Blood 58 1981 1203 1212
11. A.K. Burnett, A.H. Goldstone, and R.M. Stevens Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties Lancet 351 1998 700 708
12. R.A. Zittoun, F. Mandelli, and R. Willemze Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups N Engl J Med 332 1995 217 223 [see comments]
13. P.A. Cassileth, D.P. Harrington, and F.R. Appelbaum Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 339 1998 1649 1656 [see comments]
14. J.L. Harousseau, J.Y. Cahn, and B. Pignon Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Blood 90 1997 2978 2986
15. D. Campana, and C.H. Pui Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance Blood 85 1995 1416 1434
16. H.J. Adriaansen, B.C. Jacobs, M.C. Kappers-Klunne, K. Hahlen, H. Hooijkaas, and J.J. van Dongen Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers Leukemia 7 1993 472 481
17. B.D. Cheson, J.M. Bennett, and K.J. Kopecky Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 2003 4642 4649
18. C. Schoch, and T. Haferlach Cytogenetics in acute myeloid leukemia Curr Oncol Rep 4 2002 390 397
19. C. Schoch, W. Kern, S. Schnittger, W. Hiddemann, and T. Haferlach Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML Leukemia 18 2004 120 125
20. T. Haferlach, C. Schoch, and H. Loffler Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies J Clin Oncol 21 2003 256 265
21. C. Schoch, S. Schnittger, M. Klaus, W. Kern, W. Hiddemann, and T. Haferlach AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases Blood 102 2003 2395 2402
22. C. Schoch, T. Haferlach, and D. Haase Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients Br J Haematol 112 2001 118 126
23. D. Grimwade, H. Walker, and F. Oliver The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 1998 2322 2333
24. W. Kern, T. Haferlach, and C. Schoch Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial Blood 101 2003 64 70
25. E.H. Estey, Y. Shen, and P.F. Thall Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB Blood 95 2000 72 77
26. K. Wheatley, A.K. Burnett, and A.H. Goldstone A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties Br J Haematol 107 1999 69 79
27. W. Kern, and S. Schnittger Monitoring of AML by flow cytometry Curr Oncol Rep 5 2003 405 412
28. P. Lucio, A. Parreira, and M.W. van den Beemd Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL Leukemia 13 1999 419 427
29. L.W. Terstappen, S. Huang, and L.J. Picker Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow Blood 79 1992 666 677
30. L.W. Terstappen, and M.R. Loken Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry Anal Cell Pathol 2 1990 229 240
31. M.R. Loken, V.O. Shah, K.L. Dattilio, and C.I. Civin Flow cytometric analysis of human bone marrow. I. Normal erythroid development Blood 69 1987 255 263
32. M.R. Loken, V.O. Shah, K.L. Dattilio, and C.I. Civin Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development Blood 70 1987 1316 1324
33. L.W. Terstappen, S. Huang, M. Safford, P.M. Lansdorp, and M.R. Loken Sequential generations of haematopoietic colonies derived from single nonlineage-committed CD34+ Blood 77 1991 1218 1227
34. A. Macedo, A. Orfao, and J. Ciudad Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease Leukemia 9 1995 1896 1901
35. L.J. Smith, J.E. Curtis, H.A. Messner, J.S. Senn, H. Furthmayr, and E.A. McCulloch Lineage infidelity in acute leukemia Blood 61 1983 1138 1145
36. D. Campana, E. Coustan-Smith, and F.G. Behm The definition of remission in acute leukemia with immunologic techniques Bone Marrow Transplant 8 1991 429 437
37. D. Drach, S. Zhao, and J. Drach Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype Blood 80 1992 2729 2734 [see comments]
38. A. Venditti, F. Buccisano, and G. Del Poeta Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia Blood 96 2000 3948 3952
39. J.F. San Miguel, M.B. Vidriales, and C. Lopez-Berges Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood 98 2001 1746 1751
40. J.F. San Miguel, A. Martinez, and A. Macedo Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood 90 1997 2465 2470
41. W. Kern, S. Danhauser-Riedl, and R. Ratei Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow Haematologica 88 2003 646 653
42. W. Kern, D. Voskova, S. Schnittger, C. Schoch, W. Hiddemann, and T. Haferlach Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in patients with acute myeloid leukemia Blood 102 2003 100a
43. W. Kern, D. Voskova, C. Schoch, S. Schnittger, W. Hiddemann, and T. Haferlach Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia Blood 102 2003 876a
44. W. Kern, C. Schoch, and W. Hiddemann Prognostic significance of cytogenetics in relapsed acute myeloid leukaemia Br J Haematol 109 2000 671 672
45. H.M. Kantarjian, M.J. Keating, R.S. Walters, K.B. McCredie, and E.J. Freireich The characteristics and outcome of patients with late relapse acute myelogenous leukemia J Clin Oncol 6 1988 232 238
46. U. Oelschlagel, R. Nowak, and A. Schaub Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia Cytometry 42 2000 247 253
47. A. Macedo, J.F. San Miguel, and M.B. Vidriales Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease J Clin Pathol 49 1996 15 18
48. C.L. Reading, E.H. Estey, and Y.O. Huh Expression of unusual immunophenotype combinations in acute myelogenous leukemia Blood 81 1993 3083 3090
49. X. Thomas, L. Campos, and E. Archimbaud Surface marker expression in acute myeloid leukaemia at first relapse Br J Haematol 81 1992 40 44
50. D. Campana, S. Yokota, E. Coustan-Smith, T.E. Hansen-Hagge, G. Janossy, and C.R. Bartram The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study Leukemia 4 1990 609 614
51. D. Campana, and E. Coustan-Smith Detection of minimal residual disease in acute leukemia by flow cytometry Cytometry 38 1999 139 152
52. E. Coustan-Smith, F.G. Behm, C.A. Hurwitz, G.K. Rivera, and D. Campana N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia Leukemia 7 1993 853 858
53. K. Nakamura, K. Ogata, E. An, and K. Dan Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia Br J Haematol 108 2000 710 716
54. J. Ciudad, J.F. San Miguel, and M.C. Lopez-Berges Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia J Clin Oncol 16 1998 3774 3781
55. E. Coustan-Smith, F.G. Behm, and J. Sanchez Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 351 1998 550 554
56. W.M. Roberts, Z. Estrov, M.V. Ouspenskaia, D.A. Johnston, K.L. McClain, and T.F. Zipf Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia N Engl J Med 336 1997 317 323
57. E. Coustan-Smith, J. Sancho, and F.G. Behm Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Blood 100 2002 52 58
58. E.L. Sievers, B.J. Lange, and J.D. Buckley Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry J Natl Cancer Inst 88 1996 1483 1488
59. E. Coustan-Smith, R.C. Ribeiro, and J.E. Rubnitz Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia Br J Haematol 123 2003 243 252
60. E.L. Sievers, B.J. Lange, and T.A. Alonzo Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia Blood 101 2003 3398 3406
61. V.O. Shah, C.I. Civin, and M.R. Loken Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis J Immunol 140 1988 1861 1867
62. M.J. Borowitz, K.L. Guenther, K.E. Shults, and G.T. Stelzer Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three- color analysis Am J Clin Pathol 100 1993 534 540
63. R. Gelman, and C. Wilkening Analyses of quality assessment studies using CD45 for gating lymphocytes for CD3(+)4(+)% Cytometry 42 2000 1 4
64. R.O. Rainer, L. Hodges, and G.T. Seltzer CD 45 gating correlates with bone marrow differential Cytometry 22 1995 139 145
65. M. Roederer, S. De Rosa, and R. Gerstein 8 Color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity Cytometry 29 1997 328 339
66. E. Mensink, L.A. van de, and A. Schattenberg Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR Br J Haematol 102 1998 768 774
67. A. Hochhaus, A. Weisser, and P. La Rosee Detection and quantification of residual disease in chronic myelogenous leukemia Leukemia 14 2000 998 1005
68. E.R. Panzer-Grumayer, M. Schneider, S. Panzer, K. Fasching, and H. Gadner Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 95 2000 790 794
69. M.J. Brisco, J. Condon, and E. Hughes Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction Lancet 343 1994 196 200
70. van Dongen JJM, T. Seriu, and E.R. Panzer-Grünmayer Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1998 1731 1738
71. T. Szczepanski, A. Orfao, V. van der Velden, J.F. San Miguel, and J.J. van Dongen Minimal residual disease in leukaemia patients Lancet Oncol 2 2001 409 417
72. J.L. Schultze, and J.G. Gribben Minimal residual disease in non-Hodgkin's lymphoma Biomed Pharmacother 50 1996 451 458
73. K.C. Anderson Novel biologically based therapies for myeloma Cancer J 7 Suppl. 1 2001 S19 S23
74. J.J. van Dongen, T. Seriu, and E.R. Panzer-Grumayer Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1998 1731 1738
75. G. Marcucci, M.A. Caligiuri, and H. Dohner Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia Leukemia 15 2001 1072 1080
76. S. Schnittger, M. Weisser, C. Schoch, W. Hiddemann, T. Haferlach, and W. Kern New score predicting for prognosis in PML-RARA-, AML1-ETO-, or CBFB-MYH11-positive acute myeloid leukemia based on quantification of fusion transcripts Blood 102 2003 2746 2755
77. S. Buonamici, E. Ottaviani, and N. Testoni Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state Blood 99 2002 443 449
78. A. Guerrasio, C. Pilatrino, and D. De Micheli Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts Leukemia 16 2002 1176 1181
79. R.E. Gallagher, B.Y. Yeap, and W. Bi Quantitative real-time RT-PCR analysis of PML-RAR{alpha} mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129 Blood 101 2003 2521 2528
80. J. Krauter, K. Gorlich, and O. Ottmann Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias J Clin Oncol 21 2003 4413 4422
81. D. Grimwade, H. Walker, and G. Harrison The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood 98 2001 1312 1320
82. K. Mrozek, K. Heinonen, and C.D. Bloomfield Clinical importance of cytogenetics in acute myeloid leukaemia Best Pract Res Clin Haematol 14 2001 19 47
83. J.C. Byrd, K. Mrozek, and R.K. Dodge Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
84. I. Plantier, J.L. Lai, E. Wattel, F. Bauters, and P. Fenaux Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up Leuk Res 18 1994 885 888
85. R.A. Larson, S.F. Williams, M.M. Le Beau, M.A. Bitter, J.W. Vardiman, and J.D. Rowley Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis Blood 68 1986 1242 1249
86. G. Martinelli, E. Ottaviani, and N. Testoni Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures Bone Marrow Transplant 24 1999 694 697
87. D.F. Claxton, P. Liu, and H.B. Hsu Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia Blood 83 1994 1750 1756
88. J.J. van Dongen, E.A. Macintyre, and J.A. Gabert Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia Leukemia 13 1999 1901 1928
89. T. Miyamoto, K. Nagafuji, M. Harada, and Y. Niho Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia Leuk Lymphoma 25 1997 69 75
90. M.A. Sanz, G. Martin, and C. Rayon A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group Blood 94 1999 3015 3021
91. G. Avvisati, F. Lo Coco, and D. Diverio AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study Blood 88 1996 1390 1398
92. R.A. Perego, P. Marenco, and C. Bianchi PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation Leukemia 10 1996 207 212
93. E. Koller, H. Karlic, and O. Krieger Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia Ann Hematol 70 1995 75 78
94. L. Korninger, P. Knobl, and K. Laczika PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months Br J Haematol 88 1994 427 431
95. K. Laczika, G. Mitterbauer, and L. Korninger Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study Leukemia 8 1994 1 5
96. D. Diverio, P.P. Pandolfi, and A. Biondi Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission Blood 82 1993 3556 3559
97. W. Huang, G.L. Sun, and X.S. Li Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse Blood 82 1993 1264 1269
98. W.H. Miller Jr., K. Levine, A. DeBlasio, S.R. Frankel, E. Dmitrovsky, and R.P. Warrell Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA Blood 82 1993 1689 1694
99. J.G. Jurcic, S.D. Nimer, D.A. Scheinberg, T. DeBlasio, R.P. Warrell Jr., and W.H. Miller Jr. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia Blood 98 2001 2651 2656
100. A.K. Burnett, D. Grimwade, E. Solomon, K. Wheatley, and A.H. Goldstone Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial Blood 93 1999 4131 4143
101. K. Ikeda, K. Sasaki, and T. Tasaka PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome Int J Hematol 60 1994 197 205
102. F. Lo Coco, D. Diverio, B. Falini, A. Biondi, C. Nervi, and P.G. Pelicci Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia Blood 94 1999 12 22
103. E. Lengfelder, A. Reichert, and C. Schoch Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group Leukemia 14 2000 1362 1370
104. M.S. Tallman, C. Nabhan, J.H. Feusner, and J.M. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood 99 2002 759 767
105. F. Lo Coco, D. Diverio, B. Falini, A. Biondi, C. Nervi, and P.G. Pelicci Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia Blood 94 1999 12 22
106. D. Grimwade The significance of minimal residual disease in patients with t(15;17) Best Pract Res Clin Haematol 15 2002 137 158
107. K. Ikeda, K. Sasaki, and T. Tasaka PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome Int J Hematol 60 1994 197 205
108. L. Korninger, P. Knobl, and K. Laczika PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months Br J Haematol 88 1994 427 431
109. D. Diverio, V. Rossi, and G. Avvisati Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion genes in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP Multicenter "AIDA" Trial. GIMEME-AIEOP Multicenter "AIDA" Trial Blood 92 1998 784 789
110. K. Inokuchi, R. Iwakiri, and M. Futaki Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow Leuk Lymphoma 29 1998 553 561
111. K.S. Chang, Y.H. Fan, and S.A. Stass Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia Oncogene 8 1993 983 988
112. G. Nucifora, R.A. Larson, and J.D. Rowley Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission Blood 82 1993 712 715
113. G. Marcucci, M.A. Caligiuri, and C.D. Bloomfield Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions Blood 90 1997 5022 5024
114. K. Tobal, J. Newton, and M. Macheta Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse Blood 95 2000 815 819
115. R. Costello, D. Sainty, and D. Blaise Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia Blood 89 1997 2222 2223
116. K. Tobal, P.R. Johnson, M.J. Saunders, C.J. Harrison, and J.A. Liu Yin Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission Br J Haematol 91 1995 104 108
117. G. Nucifora, R.A. Larson, and J.D. Rowley Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission Blood 82 1993 712 715
118. P.A. Evans, M.A. Short, and A.S. Jack Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML Leukemia 11 1997 364 369
119. K. Laczika, M. Novak, and B. Hilgarth Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study J Clin Oncol 16 1998 1519 1525
120. M.J. Pongers-Willemse, T. Seriu, and F. Stolz Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia Leukemia 13 1999 110 118
121. P.J. Sykes, S.H. Neoh, M.J. Brisco, E. Hughes, J. Condon, and A.A. Morley Quantitation of targets for PCR by use of limiting dilution BioTechniques 13 1992 444 449
122. R.A. Vescio, E.J. Han, and G.J. Schiller Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts Bone Marrow Transplant 18 1996 103 110
123. A. Hochhaus, A. Reiter, and S. Saussele Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group Blood 95 2000 62 66
124. K. Tobal, and J.A. Yin Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21) Blood 88 1996 3704 3709
125. H. Cave, C. Guidal, and P. Rohrlich Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes Blood 83 1994 1892 1902
126. C.A. Heid, J. Stevens, K.J. Livak, and P.M. Williams Real time quantitative PCR Genome Res 6 1996 986 994
127. S. Galimberti, F. Brizzi, M. Mameli, and M. Petrini An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection Leuk Res 23 1999 921 929
128. P.A. Evans, M.A. Short, and R.G. Owen Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia J Clin Oncol 16 1998 3616 3627
129. R. Luthra, J.A. McBride, S. Hai, F. Cabanillas, and W.C. Pugh The application of fluorescence-based PCR and PCR-SSCP to monitor the clonal relationship of cells bearing the t(14;18)(q32;q21) in sequential biopsy specimens from patients with follicle center cell lymphoma Diagn Mol Pathol 6 1997 71 77
130. E. Delabesse, M.L. Burtin, and C. Millien Rapid, multifluorescent TCRG Vgamma and Jgamma typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations Leukemia 14 2000 1143 1152
131. M.P. Wattjes, J. Krauter, S. Nagel, O. Heidenreich, A. Ganser, and G. Heil Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia Leukemia 14 2000 329 335
132. G. Marcucci, K.J. Livak, W. Bi, M.P. Strout, C.D. Bloomfield, and M.A. Caligiuri Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay Leukemia 12 1998 1482 1489
133. J. Krauter, M.P. Wattjes, and S. Nagel Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients Br J Haematol 107 1999 80 85
134. J. Krauter, W. Hoellge, and M.P. Wattjes Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR Genes Chromosomes Cancer 30 2001 342 348
135. B. Cassinat, F. Zassadowski, and N. Balitrand Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR Leukemia 14 2000 324 328
136. N. Pallisgaard, N. Clausen, H. Schroder, and P. Hokland Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript Genes Chromosomes Cancer 26 1999 355 365
137. K. Tobal, J. Newton, and M. Macheta Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse Blood 95 2000 815 819
138. S. Tyagi, and F.R. Kramer Molecular beacons: probes that fluoresce upon hybridization Nat Biotechnol 14 1996 303 308
139. N. Thelwell, S. Millington, A. Solinas, J. Booth, and T. Brown Mode of action and application of Scorpion primers to mutation detection Nucleic Acids Res 28 2000 3752 3761
140. J.B. de Kok, E.T. Wiegerinck, B.A. Giesendorf, and D.W. Swinkels Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes) Hum Mutat 19 2002 554 559
141. J. Isacsson, H. Cao, and L. Ohlsson Rapid and specific detection of PCR products using light-up probes Mol Cell Probes 14 2000 321 328
142. C. Eckert, O. Landt, and T. Taube Potential of LigthCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 14 2000 316 323
143. E. Beillard, N. Pallisgaard, and V. van der Velden Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer Program Leukemia 17 2003 2474 2486
144. M. Weisser, C. Schoch, T. Haferlach, W. Hiddemann, and S. Schnittger Quantitative analysis of AML1-ETO fusion transcripts in t(8;21) positive AML using real-time RT-PCR W. Dietmaier C. Wittwer N. Sivasubramanian Genetics and oncology 2002 Springer-Verlag 1 10
145. M. Weisser, C. Schoch, T. Haferlach, W. Hiddemann, and S. Schnittger The choice of house keeping genes in MRD-quantification of AML1-ETO positive acute myeloid leukemia C. Wittwer M. Hahn K. Kaul Rapid cycle real-time PCR, methods and application, quantification 2003 Springer 1 10
146. J. Gabert, E. Beillard, and V. van der Velden Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program Leukemia 17 2003 2318 2357
147. V. van der Velden, A. Hochhaus, G. Cazzaniga, T. Szczepanski, J. Gabert, and J.J. van Dongen Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and
148. J. Krauter, M.P. Wattjes, and S. Nagel Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients Br J Haematol 107 1999 80 85
149. J. Krauter, W. Hoellge, and M.P. Wattjes Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR Genes Chromosomes Cancer 30 2001 342 348
150. C. Scholl, H. Breitinger, R.F. Schlenk, H. Dohner, S. Frohling, and K. Dohner Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia Genes Chromosomes Cancer 38 2003 274 280
151. M. Weisser, W. Kern, C. Schoch, W. Hiddemann, T. Haferlach, and S. Schnittger Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukaemia Haematologica 90 2005 881 889
152. K. Wheatley, A.K. Burnett, and A.H. Goldstone A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties Br J Haematol 107 1999 69 79
153. W. Kern, T. Haferlach, and C. Schoch Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial Blood 101 2003 64 70
154. S. Nguyen, T. Leblanc, and P. Fenaux A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup Blood 99 2002 3517 3523
155. P.D. Kottaridis, R.E. Gale, and M.E. Frew The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
156. S. Schnittger, A. Kohlmann, M. Dugas, C. Schoch, W. Kern, and W. Hiddemann Acute myeloid leukemia (AML) with FLT3-length mutations (FLT3-LM) can be discriminated from AML without FLT3-LM in distinct AML-subtypes based on specific gene expression profiles Blood 100 11 2002
157. C. Thiede, C. Steudel, and B. Mohr Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
158. S. Frohling, R.F. Schlenk, and J. Breitruck Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm Blood 100 2002 4372 4380
159. S. Schnittger, C. Schoch, and M. Dugas Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59 66
160. R. Hovland, B.T. Gjertsen, and O. Bruserud Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases Leuk Lymphoma 43 2002 2027 2029
161. P.D. Kottaridis, R.E. Gale, S.E. Langabeer, M.E. Frew, D.T. Bowen, and D.C. Linch Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood 100 2002 2393 2398
162. L.Y. Shih, C.F. Huang, and J.H. Wu Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse Blood 100 2002 2387 2392
163. D.G. Gilliland Murky waters for MRD detection in AML: flighty FLT3/ITDs Blood 100 2002 2277
164. S. Schnittger, C. Schoch, W. Kern, W. Hiddemann, and T. Haferlach FLT3-length mutations as marker for follow up studies in acute myeloid leukaemia Acta Haematol 112 2004 68 78
165. W. Kern, T. Haferlach, S. Schnittger, W.D. Ludwig, W. Hiddemann, and C. Schoch Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy Leukemia 16 2002 2084 2091
166. M. Libura, V. Asnafi, and A. Tu FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress Blood 102 2003 2198 2204
167. S.D. Lyman, and S.E. Jacobsen c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities Blood 91 1998 1101 1134
168. S.P. Whitman, K.J. Archer, and L. Feng Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study Cancer Res 61 2001 7233 7239
169. P.D. Kottaridis, R.E. Gale, and D.C. Linch Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia Leuk Lymphoma 44 2003 905 913
170. Y. Nakano, H. Kiyoi, and S. Miyawaki Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene Br J Haematol 104 1999 659 664
171. M. Nakao, J.W. Janssen, D. Erz, T. Seriu, and C.R. Bartram Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease Leukemia 14 2000 522 524
172. D.L. Stirewalt, C.L. Willman, and J.P. Radich Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific Leuk Res 25 2001 1085 1088
173. S. Schnittger, C. Schoch, W. Kern, T. Haferlach, and W. Hiddemann FLT3-LM and MLL-PTD as markers for PCR-based detection of minimal residual disease (MRD) in AML with normal karyotype Blood 98 2001 581A
174. S. Schnittger, B. Wormann, W. Hiddemann, and F. Griesinger Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors Blood 92 1998 1728 1734
175. S. Schnittger, U. Kinkelin, and C. Schoch Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML Leukemia 14 2000 796 804
176. M.A. Caligiuri, S.A. Schichman, and M.P. Strout Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations Cancer Res 54 1994 370 373
177. M.A. Caligiuri, M.P. Strout, and S.A. Schichman Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11 Cancer Res 56 1996 1418 1425
178. S.A. Schichman, M.A. Caligiuri, and Y. Gu ALL-1 partial duplication in acute leukemia Proc Natl Acad Sci USA 91 1994 6236 6239
179. S. Schnittger, C. Thiede, and W. Kern Partial tandem duplication of the MLL-gene (MLL-PTD): a metaanalysis of 2885 AML patients enrolled into the German AMLCG99 and AML96 SHG trials Blood 102 2003 [Abstract]
180. C. Steudel, M. Wermke, and M. Schaich Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia Genes Chromosomes Cancer 37 2003 237 251
181. K. Dohner, K. Tobis, and R. Ulrich Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm J Clin Oncol 20 2002 3254 3261
182. M. Gessler, A. Poustka, W. Cavenee, R.L. Neve, S.H. Orkin, and G.A. Bruns Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping Nature 343 1990 774 778
183. L. Bergmann, C. Miething, and U. Maurer High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome Blood 90 1997 1217 1225
184. L. Bergmann, U. Maurer, and E. Weidmann Wilms tumor gene expression in acute myeloid leukemias Leuk Lymphoma 25 1997 435 443
185. E. Niegemann, S. Wehner, B. Kornhuber, D. Schwabe, and U. Ebener wt1 gene expression in childhood leukemias Acta Haematol 102 1999 72 76
186. M. Weisser, W. Kern, S. Rauhut, C. Schoch, W. Hiddemann, T. Haferlach, and S. Schnittger Prognostic impact of RT-PCR based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukaemia Leukemia 19 2005 1416 1423
187. N. Hosen, Y. Sonoda, and Y. Oji Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells Br J Haematol 116 2002 409 420
188. U. Maurer, E. Weidmann, T. Karakas, D. Hoelzer, and L. Bergmann Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors Blood 90 1997 4230 4232
189. U. Maurer, J. Brieger, E. Weidmann, P.S. Mitrou, D. Hoelzer, and L. Bergmann The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro Exp Hematol 25 1997 945 950
190. P.N. Baird, and P.J. Simmons Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis Exp Hematol 25 1997 312 320
191. K. Inoue, H. Sugiyama, and H. Ogawa WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia Blood 84 1994 3071 3079
192. K. Inoue, H. Ogawa, and Y. Sonoda Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia Blood 89 1997 1405 1412
193. K.A. Kreuzer, A. Saborowski, and J. Lupberger Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias Br J Haematol 114 2001 313 318
194. H.D. Menssen, J.M. Siehl, and E. Thiel Wilms tumor gene (WT1) expression as a panleukemic marker Int J Hematol 76 2002 103 109
195. A.H. Elmaagacli, D.W. Beelen, R. Trenschel, and U.W. Schaefer The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation Bone Marrow Transplant 25 2000 91 96
196. K. Suzukawa, E. Parganas, and A. Gajjar Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26) Blood 84 1994 2681 2688
197. K. Morishita, E. Parganas, T. Matsugi, and J.N. Ihle Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor Mol Cell Biol 12 1992 183 189
198. G. Nucifora The EVI1 gene in myeloid leukemia Leukemia 11 1997 2022 2031
199. S. Schnittger, C. Schoch, G. Mellert, T. Haferlach, and W. Hiddemann Expression of EVI1 is not specific for AML with 3q21q26 aberrations Blood 94 1999 497a
200. S.E. Langabeer, J.R. Rogers, and G. Harrison EVI1 expression in acute myeloid leukaemia Br J Haematol 112 2001 208 211
201. S. Schnittger, W. Kern, C. Schoch, W. Hiddemann, and T. Haferlach Analysis of EVI1 expression in 270 cases with AML at diagnosis and evaluation as a marker for follow up analysis using quantitative RT-PCR in 36 cases Blood 102 2003 [Abstract]
202. Barjesteh van Waalwijk van Doorn, C. Erpelinck, and W.L. van Putten High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients Blood 101 2003 837 845
203. W. Kern, C. Schoch, T. Haferlach, D. Voskova, W. Hiddemann, and S. Schnittger Complemental roles for multiparameter flow cytomety and quantitative RT-PCR for the quantification of minimal residual disease in patients with acute myeloid leukemia Blood 2003 102
204. D. Voskova, C. Schoch, S. Schnittger, W. Hiddemann, T. Haferlach, and W. Kern Stability of leukaemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings Clin Cytom 62B 2004 25 38